Life sciences venture firm Foresite Capital said today that it raised a record $668 million for its fourth fund, bringing its assets-under-management tally to $2 billion.
San Francisco-based Foresite was founded in 2011 by former Theravance co-founder & CEO Dr. Jim Tananbaum. Investors in its fourth fund include “a significant representation of existing investors, including university endowments, pension funds, insurance companies and foundations” and some new investors, the company said today.
“At Foresite Capital we’ve brought together a unique value proposition for our portfolio companies. We not only provide capital from seed to public stage, but also a multidisciplinary team of scientists, clinicians, analysts and engineers who collaborate to seek the best data-driven decisions. The ability to ingest and derive meaning from massive amounts of complex information is a critical success factor in healthcare investing,” Tananbaum said in prepared remarks. “We’re pleased by the confidence and enthusiasm our Fund IV investors have demonstrated in the Foresite Capital team, as well as the progress made by our rapidly developing portfolio.”
“We are focused on meaningfully improving patient health and well-being. We are privileged to work with creative healthcare and life sciences entrepreneurs, whose efforts continue to advance our understanding of disease and provide innovative approaches to address patient needs,” added managing director Dr. Dorothy Margolskee.
Foresite has a stake in several big-name life science outfits, including Intarcia Therapeutics, Aerie Pharmaceuticals and 10x Genomics.
